|
Mutation Information
|
Mutation Site
|
S219A |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
s.S210R+rt.S219A |
|
Viral Reference
|
X02763.1;
X65259.1 |
|
Country
|
Italy |
Literature Information
|
PubMed PMID
|
28152517
|
|
Disease
|
Chronic hepatitis B
|
|
Published Year
|
2017 |
|
Journal
|
Oncotarget |
|
Title
|
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro. |
|
Author
|
Salpini R,Surdo M,Warner N,Cortese MF,Colledge D,Soppe S,Bellocchi MC,Armenia D,Carioti L,Continenza F,Di Carlo D,Saccomandi P,Mirabelli C,Pollicita M,Longo R,Romano S,Cappiello G,Spanò A,Trimoulet P,Fleury H,Vecchiet J,Iapadre N,Barlattani A,Bertoli A,Mari T,Pasquazzi C,Missale G,Sarrecchia C,Orecchini E,Michienzi A,Andreoni M,Francioso S,Angelico M,Verheyen J,Ceccherini-Silberstein F,Locarnini S,Perno CF,Svicher V |
|
Evidence
|
The percentage of patients with sS210R/rtS219A was comparable between drug naïve HCC-patients (33.3%, 3/9) and drug-treated HCC-patients (35.7%, 5/14), thus excluding the impact of antiviral therapy on the selection of this mutation.
|
|
|
HBV Mutation Detail Information